ArriVent BioPharma said it is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib. The statement follows a trading halt. No results or decisions were disclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
